News & Resources


IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards!

We’re proud to announce that IXICO has been named CRO Provider of the Year at the Precision Medicine Awards 2025, hosted by Oxford Global. This award celebrates our commitment to advancing precision in neuroscience through cutting-edge neuroimaging and AI-powered analytics.

Why Partnerships are the Promising Pathway for Alzheimer’s Breakthroughs

Why Partnerships are the Promising Pathway for Alzheimer’s Breakthroughs Strategic collaborations are key to improving the pace and access to research In collaboration with the Global Alzheimer's Platform Foundation Undiagnosed and Overlooked Everyone knows someone impacted by Alzheimer’s disease (AD), as it affects an estimated 55 million people worldwide.


Global clinical trial contract wins in Alzheimer’s Disease and Friedreich’s Ataxia

12 August 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications.

The New Research Developments Driving Precision Care in Parkinson’s Disease

Parkinson’s disease (PD) research is advancing rapidly, driven by innovations in neuroimaging, biomarker science, and therapeutic development. The field is moving beyond symptom management toward biologically grounded strategies for early diagnosis, disease staging, and modification. Biomarker-Driven Staging: The NSD-ISS Framework A major shift is underway in how PD is diagnosed and staged.


IXICO and Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership for the Transformative Bio-Hermes-002 Study

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias  London, UK July.

Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme

Imaging of Neurodegeneration within the NIA-AA Research Framework: The ‘N’ in the AT(N) Scheme Alzheimer’s disease (AD) is the most common form of dementia, affecting millions globally. As research shifts increasingly toward earlier diagnosis and targeted interventions, including risk factors, biomarker-based frameworks have become essential tools for guiding both clinical research and drug development.


Revenues anticipated to be ahead of expectations for the year ending 30 September 2025

17 July 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today provides a trading update for the financial year ending 30 September 2025. The Company anticipates revenues to be at least £6.

1-8 of 170 results